Mason’s Michael Buschmann and team at start-up AexeRNA Therapeutics Inc. pursue patents for improved COVID-19 vaccines

Published on :

George Mason University bioengineering professor Michael Buschmann and a team of scientific collaborators have devised improved lipid nanoparticle technologies to deliver mRNA that could make mRNA vaccines such as the COVID-19 vaccines less costly, with fewer side-effects and more available worldwide.

Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility in Frederick, MD to Accelerate Development of Vaccines and Antiviral Drugs

Published on :

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development (R&D) facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.

Rockefeller Foundation Grant Aims to Boost Vaccinations Among African American Communities

Published on :

Fueled by a $400,000 grant from The Rockefeller Foundation, the Black Women’s Health Imperative (BWHI), based in Washington, D.C., aims to improve vaccination rates among the African-American community through outreach programs and strategic partnerships with like-minded coalitions, including the National Caucus & Center on Black Aging (NCBA) and National Coalition of 100 Black Women (NCBW).

Novavax Vaccine Could Generate $33 Billion in Revenue through 2027, Analyst Says

Published on :

Novavax is aiming to seek Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 later this spring. If the U.S. Food and Drug Administration gives it the green light, the Maryland-based company could see revenue of approximately $1.8 billion in sales by the end of the year.

Emergent Rallies to Meet COVID-19 Vaccine Supply Challenge

Published on :

Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

Published on :

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., February 4, 2021 [….]

ATCC Announces Award of HIV Reagent Program

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines and microorganisms.
Published on :

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.